Clinical Trial

"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"

Study acronym: PHINK
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 6, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase I / II study on infusion of alloreactive or stimulated Natural Killer cells with IL-15 ex vivo after haploidentical transplantation of hematopoietic progenitors in pediatric patients with hematologic malignancies (PHINK
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-03-30.
Status change: Recruiting → Active, Not Recruiting 2025-04-03
Trial Details
NCT Number NCT05304754
Lead Sponsor Instituto de Investigación Hospital Universitario La Paz
Conditions High-risk Leukemias
Enrollment 18 participants
Start Date 2020-11-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-04-06